Table of Contents: CATIE TreatmentUpdate

Table of Contents: CATIE TreatmentUpdate - 2002

Canadian AIDS Treatment Information Exchange
Edited by: Sean Hosein

Jump to Table of Contents

TreatmentUpdate 128: July - Vol. 14, No. 5

English

Françaises

ANTI-HIV AGENTS: Starting therapy: study finds guidelines linked to level of immunity
AGENTS ANTI-VIH: Le début du traitement : une étude confirme le bien-fondé des lignes directrices: HoseinSR; The immune system has a number of ways of dealing with HIV-infected cells...
ANTI-CANCER AGENTS: Recurring cervical growths
AGENTS ANTICANCÉREUX: Des lésions cervicales récurrentes: HoseinSR; HIV positive women are at increased risk for the development of abnormal growths on their cervix. These growths are caused by infection with human papilloma virus (HPV), a sexually transmitted infection. In some cases, the growths regress or shrink without treatment. In other cases, the growth may become cancerous. Regular Pap smears and gynecologic examinations are therefore an important part of health care for HIV positive women.
SIDE EFFECTS: Study finds problems with reporting side effects
EFFETS SECONDAIRES: Une étude révèle des problèmes de signalement des effets secondaires: HoseinSR; Drugs are first tested in clinical trials to assess their safety and effectiveness before being approved for sale. However, not all side effects caused by drugs — adverse drug reactions (ADRs) — are identified in clinical trials. Indeed, in one study, a large proportion of ADRs was not detected before drugs were approved for sale.
SIDE EFFECTS: Male sexual dysfunction and HAART — the confusion continues
EFFETS SECONDAIRES: La dysfonction sexuelle masculine et la multithérapie – la confusion persiste: HoseinSR; The use of highly active antiretroviral therapy (HAART) has extended the survival of people with HIV/AIDS (PHAs) who can adhere to and tolerate these medications. As PHAs live longer, issues related to quality of life begin to have more importance. One of these issues is sexual dysfunction. Most studies in PHAs dealing with this subject have been on males.
SIDE EFFECTS: Sexual dysfunction in men: A report from Boston
EFFETS SECONDAIRES: La dysfonction sexuelle masculine : un rapport de Boston: HoseinSR; Researchers at a number of care facilities in Boston reviewed medical records of HIV positive men whose data were recorded between January 1993 and November 1998. In searching through the records, the researchers focused on 254 adult males who used protease inhibitors (PIs) and who had the following profile at the start of the study...
SIDE EFFECTS: Sexual dysfunction in men: A report from France
EFFETS SECONDAIRES: La dysfonction sexuelle masculine : un rapport de France: HoseinSR; Researchers in Paris, France, conducted a study on 156 HIV positive men who were taking a variety of anti-HIV treatment regimens. The purpose of this study was to find out about the relation between treatment and sexual dysfunction. According to their results, about 71% of subjects experienced "some degree" of sexual dysfunction since they began therapy. However, there appeared to be no link between the use of protease inhibitors (PIs) and sexual dysfunction.

TreatmentUpdate 132: December - Vol. 14, No. 9: INTRODUCTION: What's a conference about ?; SIDE EFFECTS: Who gets treatment and... side effects; SIDE EFFECTS: Protection from nuke side effects; SIDE EFFECTS: Breaking free from nukes; ADHERENCE: What helps adherence to therapy?; VACCINES: Rub-on vaccine study planned; CANCER: Cancer risk falls in some HAART users; INFECTIONS: Syphilis - the great masquerader; INFECTIONS: Is hepatitis C virus going to become a major STD
TreatmentUpdate 131: November - Vol. 14, No. 8: SIDE EFFECTS: The usual suspects; SIDE EFFECTS: A brief history of HIV drug therapy; SIDE EFFECTS: Strange side effects; SIDE EFFECTS: Focus on fat; SIDE EFFECTS: Lots of volunteers needed; SIDE EFFECTS: Lactic acid and nuke damage; SIDE EFFECTS: No nukes please; SIDE EFFECTS: Fat wasting - AZT vs. d4T; SIDE EFFECTS: Sugar blues; SIDE EFFECTS: Predicting body shape changes; SIDE EFFECTS: Niacin for high triglycerides; SIDE EFFECTS: Supplement fix for nelfinavir-related diarrhea
TreatmentUpdate 130: September/October - Vol. 14, No. 7: ANTI-HIV AGENTS - Drug holidays - an overview ; ANTI-HIV AGENTS - Here's a story about a drug holiday ; TOXICITY - Milk thistle and indinavir ; TESTING - Some factors affecting survival in HIV positive women ; ANTI-CANCER AGENTS - A new treatment for Kaposi's sarcoma
TreatmentUpdate 129: August - Vol. 14, No. 6: THE XIV INTERNATIONAL AIDS CONFERENCE - Overview of conferencel; ANTI-HIV AGENTS : American-Italian study produces unexpected results; ANTI-HIV AGENTS : Tenofovir looks good in initial therapy; ANTI-HIV AGENTS : Tenofovir and Videx (ddI) EC — some caution required; ANTI-HIV AGENTS : T-20 shows its potency; ANTI-HIV AGENTS : Efavirenz makes its mark in AIDS; TESTING : Study finds fatigue linked to quality of sleep; TESTING : High liver enzyme levels — a warning about survival?; NUTRITION : Nutrient deficits found in some HIV positive people; NUTRITION : Low zinc intake linked to reduced survival
TreatmentUpdate 128: July - Vol. 14, No. 5: SIDE EFFECTS: Sexual dysfunction in men: A report from France; SIDE EFFECTS: Sexual dysfunction in men: A report from Boston; SIDE EFFECTS: Male sexual dysfunction and HAART — the confusion continues; SIDE EFFECTS: Study finds problems with reporting side effects; ANTI-CANCER AGENTS: Recurring cervical growths; ANTI-HIV AGENTS: Starting therapy: study finds guidelines linked to level of immunity
TreatmentUpdate 127: May/June - Vol. 14, No. 4: ANTI-HIV AGENTS: Delavirdine in rescue regimens; ANTI-HIV AGENTS: Could cimetidine be used as a booster?; ANTI-HIV AGENTS: Teaching adherence to substance users; Fine-tuning saquinavir; ANTI-HIV AGENTS: Invirase vs. Fortovase: unexpected results?; ANTI-HIV AGENTS: Saquinavir once daily; ANTI-HIV AGENTS: Saquinavir with low-dose ritonavir twice daily; ANTI-HIV AGENTS: Highlights from the 3rd International Workshop on Clinical Pharmacology of HIV Therapy
TreatmentUpdate 126: March - Vol. 14, No. 3: SIDE EFFECTS : Protease inhibitors and lipid-lowering drugs -- interactions; Cause of serious illness among HAART-users not clear; Using abacavir to avoid lipid problems; Switching to abacavir to reduce fat wasting; 9th Retrovirus Overview; SIDE EFFECTS : Assessing nuke toxicity; SIDE EFFECTS : Check-ups for the power plant?; SIDE EFFECTS : Damage to the power plant
TreatmentUpdate 125: February - Vol. 14, No. 2: SIDE EFFECTS: Comparing liver toxicity between efavirenz and nevirapine; SIDE EFFECTS: Nevirapine levels may predict toxicity; SIDE EFFECTS: Health Canada advises against kava; SIDE EFFECTS: Birth defect in baby born to efavirenz-user; SIDE EFFECTS: Viagra and grapefruit juice - not a good mix; INFECTION FIGHTERS: Cidofovir and surgery for genital warts; ANTI-HIV AGENTS: Swiss study switching to efavirenz
TreatmentUpdate 124: January - Vol. 14, No. 1: SIDE EFFECTS: Testosterone troubles; SIDE EFFECTS: Growth hormone: Does less equal more?; SIDE EFFECTS: Thyroid troubles in Montreal; SIDE EFFECTS: Thyroid troubles in France; HIGHLIGHTS FROM ICAAC: Directly observed therapy (DOT); HIGHLIGHTS FROM ICAAC: Amprenavir and low-dose ritonavir; HIGHLIGHTS FROM ICAAC: Saquinavir vs. Sustiva once daily; HIGHLIGHTS FROM ICAAC: Tenofovir; HIGHLIGHTS FROM ICAAC: Atazanavir boosts saquinavir; HIGHLIGHTS FROM ICAAC: Atazanavir vs. nelfinavir; HIGHLIGHTS FROM ICAAC: Atazanavir overview; ANTI-HIV AGENTS: Starting HAART and its effect on survival; ANTI-HIV AGENTS: Response to HAART depends on T-cell count; ANTI-HIV AGENTS: Delaying therapy - the pendulum swings back
Copyright / Staff / How to Contact

ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990,2002. ÆGiS . All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS , or the party credited as the provider of the content. Please contact the party credited as the provider of the content for permission to reproduce.

TreatmentUpdate 128: July - Vol. 14, No. 5

Table Of Contents